Syros Pharmaceuticals Closes IPO

7/6/16

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Syros Pharmaceuticals (NASDAQ: SYRS) today announced the closing of its initial public offering of 4,600,000 shares of common stock at an offering price of $12.50 per share, including 600,000 shares of common stock issued upon the full exercise by the underwriters of their option to purchase additional shares. All of the shares in the offering were sold by Syros. The gross proceeds from the initial public offering were approximately $57.5 million, before underwriting discounts, commissions and estimated offering expenses. The Company’s common stock is listed on the NASDAQ Global Select Market under the ticker symbol “SYRS.”

Cowen and Company and Piper Jaffray & Co. acted as joint book-running managers for the offering. JMP Securities acted as lead manager for the offering, and Wedbush PacGrow acted as co-manager for the offering.

About Syros Pharmaceuticals

Syros Pharmaceuticals is pioneering the understanding of the non-coding region of the genome to advance a new wave of medicines that control expression of disease-driving genes. Syros has built a proprietary platform that is designed to systematically and efficiently analyze this unexploited region of DNA in human disease tissue to identify and drug novel targets linked to genomically defined patient populations.

Recent Deals

Interested in advertising your deals? Contact Edwin Warfield.